Calcium Phosphate As a Key Material for Socially Responsible Tissue Engineering
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
LGM-Pharma-Regulatory-1527671011
Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide -
Educate Your Patients About Kidney Stones a REFERENCE GUIDE for HEALTHCARE PROFESSIONALS
Educate Your Patients about Kidney Stones A REFERENCE GUIDE FOR HEALTHCARE PROFESSIONALS Kidney stones Kidney stones can be a serious problem. A kidney stone is a hard object that is made from chemicals in the urine. There are five types of kidney stones: Calcium oxalate: Most common, created when calcium combines with oxalate in the urine. Calcium phosphate: Can be associated with hyperparathyroidism and renal tubular acidosis. Uric acid: Can be associated with a diet high in animal protein. Struvite: Less common, caused by infections in the upper urinary tract. Cystine: Rare and tend to run in families with a history of cystinuria. People who had a kidney stone are at higher risk of having another stone. Kidney stones may also increase the risk of kidney disease. Symptoms A stone that is small enough can pass through the ureter with no symptoms. However, if the stone is large enough, it may stay in the kidney or travel down the urinary tract into the ureter. Stones that don’t move may cause significant pain, urinary outflow obstruction, or other health problems. Possible symptoms include severe pain on either side of the lower back, more vague pain or stomach ache that doesn’t go away, blood in the urine, nausea or vomiting, fever and chills, or urine that smells bad or looks cloudy. Speak with a healthcare professional if you feel any of these symptoms. Risk factors Risk factors can include a family or personal history of kidney stones, diets high in protein, salt, or sugar, obesity, or digestive diseases or surgeries. -
Protocol Supplementary
Optimal Pharmacological Management and Prevention of Glucocorticoid-Induced Osteoporosis (GIOP) Protocol for a Systematic Review and Network Meta-Analysis Supplementary Materials: Sample Search Strategy Supplementary 1: MEDLINE Search Strategy Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Line 1 exp Osteoporosis/ 2 osteoporos?s.ti,ab,kf. 3 Bone Diseases, Metabolic/ 4 osteop?eni*.ti,ab,kf. 5 Bone Diseases/ 6 exp Bone Resorption/ 7 malabsorption.ti,ab,kf. 8 Bone Density/ 9 BMD.ti,ab,kf. 10 exp Fractures, Bone/ 11 fracture*.ti,ab,kf. 12 (bone* adj2 (loss* or disease* or resorption* or densit* or content* or fragil* or mass* or demineral* or decalcif* or calcif* or strength*)).ti,ab,kf. 13 osteomalacia.ti,ab,kf. 14 or/1-13 15 exp Glucocorticoids/ 16 exp Steroids/ 17 (glucocorticoid* or steroid* or prednisone or prednisolone or hydrocortisone or cortisone or triamcinolone or dexamethasone or betamethasone or methylprednisolone).ti,ab,kf. 18 or/15-17 19 14 and 18 20 ((glucocorticoid-induced or glucosteroid-induced or corticosteroid-induced or glucocorticosteroid-induced) adj1 osteoporos?s).ti,ab,kf. 21 19 or 20 22 exp Diphosphonates/ 23 (bisphosphon* or diphosphon*).ti,ab,kf. 24 exp organophosphates/ or organophosphonates/ 25 (organophosphate* or organophosphonate*).ti,ab,kf. 26 (alendronate or alendronic acid or Fosamax or Binosto or Denfos or Fosagen or Lendrate).ti,ab,kf. 27 (Densidron or Adrovance or Alenotop or Alned or Dronat or Durost or Fixopan or Forosa or Fosval or Huesobone or Ostemax or Oseolen or Arendal or Beenos or Berlex or Fosalen or Fosmin or Fostolin or Fosavance).ti,ab,kf. -
Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). -
Remineralisation of Enamel Subsurface Lesions with Casein Phosphopeptide - Amorphous Calcium Phosphate in Patients with Fixed Orthodontic Appliances
Y T E I C O S L BALKAN JOURNAL OF STOMATOLOGY A ISSN 1107 - 1141 IC G LO TO STOMA Remineralisation of Enamel Subsurface Lesions with Casein Phosphopeptide - Amorphous Calcium Phosphate in Patients with Fixed Orthodontic Appliances SUMMARY Darko Pop Acev1, Julijana Gjorgova2 One of the most common problems in everyday dental practice is the 1PZU Pop Acevi, Skopje, FYROM occurrence of dental caries. The easiest way to deal with this problem is its 2Department of Orthodontics prevention. A lot of research has been done to find a material that would “Ss. Cyril and Methodius” University, Skopje help to prevent the occurrence of dental caries, which means to stop tooth FYROM demineralization (loss of minerals from the tooth structure) and replace it with the process of remineralisation (reincorporating minerals in dental tissue). In this review article we will present the remineralisation potential of casein phosphopeptide - amorphous calcium phosphate (CPP-ACP) in clinical studies. We considered all articles that were available through the browser of Pubmed Central. After analyzing the results obtained from these studies, we concluded that casein phosphopeptide - amorphous calcium phosphate has significant remineralisation effect when used in patients with fixed orthodontic appliances. Keywords: Dental Remineralisation; Casein Phosphopeptide; Amorphous Calcium LITERATURE REVIEW (LR) Phosphate Balk J Stom, 2013; 17:81-91 Introduction of the enamel porous and sensitive to internal and external factors9. Apart of this, maintaining oral hygiene Dental caries is defined as localized destruction of is difficult in patients with fixed orthodontic appliances; tooth hard tissue with acids, produced during fermentation this is the reason for accumulating food debris on the of carbohydrates, by bacteria in dental plaque1,2. -
Spray-Dried Monocalcium Phosphate Monohydrate for Soluble Phosphate Fertilizer Khouloud Nasri, Hafed El Feki, Patrick Sharrock, Marina Fiallo, Ange Nzihou
Spray-Dried Monocalcium Phosphate Monohydrate for Soluble Phosphate Fertilizer Khouloud Nasri, Hafed El Feki, Patrick Sharrock, Marina Fiallo, Ange Nzihou To cite this version: Khouloud Nasri, Hafed El Feki, Patrick Sharrock, Marina Fiallo, Ange Nzihou. Spray-Dried Monocal- cium Phosphate Monohydrate for Soluble Phosphate Fertilizer. Industrial and engineering chemistry research, American Chemical Society, 2015, 54 (33), p. 8043-8047. 10.1021/acs.iecr.5b02100. hal- 01609207 HAL Id: hal-01609207 https://hal.archives-ouvertes.fr/hal-01609207 Submitted on 15 Jan 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Spray-Dried Monocalcium Phosphate Monohydrate for Soluble Phosphate Fertilizer Khouloud Nasri and Hafed El Feki Laboratory of Materials and Environmental Sciences, Faculty of Sciences of Sfax, Soukra Road km 4B. P. no 802−3038, Sfax, Tunisia Patrick Sharrock* and Marina Fiallo Université de Toulouse, SIMAD, IUT Paul Sabatier, Avenue Georges Pompidou, 81104 Castres, France Ange Nzihou Centre RAPSODEE, Université de Toulouse, Mines Albi, CNRS, Albi, France ABSTRACT: Monocalcium phosphate monohydrate (MCPM) was obtained by water extraction of triple superphosphate. The solubility of MCPM is 783.1 g/L, and is entirely soluble. Saturated MCPM solution dissociates into free phosphoric acid and monetite (CaHPO4), but evaporation to dryness by spray drying forms MCPM during crystallization. -
Re-Evaluated Data of Dissociation Constants of Alendronic, Pamidronic and Olpadronic Acids
Cent. Eur. J. Chem. • 7(1) • 2009 • 8-13 DOI: 10.2478/s11532-008-0099-z Central European Journal of Chemistry Re-evaluated data of dissociation constants of alendronic, pamidronic and olpadronic acids Invited Paper Alexander P. Boichenko1, Vadim V. Markov1, Hoan Le Kong1, Anna G. Matveeva2, Lidia P. Loginova1* 1Department of Chemical Metrology, Kharkov V.N. Karazin National University, 61077 Kharkov, Ukraine. 2A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russian Federation Received 01 April 2008; Accepted 23 October 2008 Abstract: The dissociation constants of (4-amino-1-hydroxybutylidene)bisphosphonic (alendronic) acid, (3-(dimethylamino)-1- hydroxypropylidene)bisphosphonic (olpadronic) acid and (3-amino-1-hydroxypropylidene)bisphosphonic (pamidronic) acid were obtained in aqueous solutions (0.10 М КСl) and micellar solutions of cetylpyridinium chloride (0.10 М CPC) at 25.0°C. With the exception of the third dissociation constant of alendronic acid, the dissociation constants of alendronic, olpadronic and pamidronic acids in aqueous solutions matched literature data. The possibility of sodium alendronate determination by acid-base titration by NaOH solution was theoretically grounded on the basis of re-evaluated data of alendronic acid dissociation constants. Keywords: Alendronate • Olpadronate, pamidronate, dissociation constant • Micellar media effect © Versita Warsaw and Springer-Verlag Berlin Heidelberg. 1. Introduction spectrometric [12], refractive index [13] and Sodium salts of (4-amino-1-hydroxybutylidene) conductometric [14] detection have been proposed. bisphosphonic (alendronic) acid, (3-(dimethylamino)- The anion-exchange chromatography with refractive 1-hydroxypropylidene)bisphosphonic (olpadronic) acid index detection is recommended by British and (3-amino-1-hydroxypropylidene)bisphosphonic Pharmacopoeia for the determination of sodium (pamidronic) acid are successfully used for the medical alendronate [15]. -
Phvwp Class Review Bisphosphonates and Osteonecrosis of the Jaw (Alendronic Acid, Clodronic Acid, Etidronic Acid, Ibandronic
PhVWP Class Review Bisphosphonates and osteonecrosis of the jaw (alendronic acid, clodronic acid, etidronic acid, ibandronic acid, neridronic acid, pamidronic acid, risedronic acid, tiludronic acid, zoledronic acid), SPC wording agreed by the PhVWP in February 2006 Section 4.4 Pamidronic acid and zoledronic acid: “Osteonecrosis of the jaw has been reported in patients with cancer receiving treatment regimens including bisphosphonates. Many of these patients were also receiving chemotherapy and corticosteroids. The majority of reported cases have been associated with dental procedures such as tooth extraction. Many had signs of local infection including osteomyelitis. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, radiotherapy, corticosteroids, poor oral hygiene). While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.” Remaining bisphosphonates: “Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelits) has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphophonates. Many of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphophonates. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. -
Phosphate & Rock
IOSR Journal of Environmental Science, Toxicology and Food Technology (IOSR-JESTFT) e-ISSN: 2319-2402,p- ISSN: 2319-2399.Volume 8, Issue 11 Ver. III (Nov. 2014), PP 22-39 www.iosrjournals.org Comparative Study Of Rock Phosphate And Calcium Phosphate On The Growth &Biochemistry Of Brassica Juncea And It’s Impact On Soil Heath Sandhya Buddh Department Of Biotechnology Boston College For Professional Studies, Gwalior Abstract: A study was conducted to compare the effect of rock phosphate & calcium phosphate on the growth and the biochemistry of the plant Brassica juncea and its impact on soil health. The rock phosphate is highly favorable than tri-calcium phosphate for the mustard growth. Physiochemical effect of the plant was evaluated through the analysis of amino acid, pigment, shoot & root biomass content of the plant. The following parameters of soil (treated with Tri calcium phosphate & Rock phosphate) such as pH, EC, moisture, ash were analyzed. The pH of the soil mixed with tri-calcium phosphate and rock phosphate was decreased slightly from original & EC was increased .Impact of rock phosphate & calcium phosphate on the soil health can be observed by calculating TOC and nitrogen estimation at regular interval of days. Nitrogen concentration at 5th day is gradually decreases except control, R2 and R4 and after in 10th day and 20th day it becomes increased. The highest TOC value was observed on 10th day i.e. (C1)9.64 in calcium phosphate and R1 (10.17) on 1st day in rock phosphate. I. Introduction Phosphorus, one of the 17 chemical elements required for plant growth and reproduction, is often referred to as the ―energizer‖ since it helps store and transfer energy during photosynthesis. -
Best Practice & Research Clinical Rheumatology
Best Practice & Research Clinical Rheumatology 24 (2010) 489e496 Contents lists available at ScienceDirect Best Practice & Research Clinical Rheumatology journal homepage: www.elsevierhealth.com/berh 5 Novel targets in bone and cartilage Christian Beyer, Georg Schett* Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany Keywords: The spectrum of arthritis ranges from erosive (e.g., rheumatoid bone arthritis) to ossifying disease with formation of new bone (e.g., anky- cartilage: FGF-18 losing spondylitis and osteoarthritis). The molecular basis for these hedgehog different patterns of arthritis had long been unclear. In the last few RANKL years, however, characterisation of catabolic and anabolic molecular sclerostin pathways in different forms of arthritis led to a better understanding of targets joint remodelling and revealed novel therapeutic targets. Wnt Recent findings show that catabolic and anabolic molecular pathways govern bone and cartilage remodelling in healthy and arthritic joints. The predominance of catabolic molecular pathways (e.g., receptor activator of nuclear factor-kB ligand (RANKL)/RANK and cathepsin K) causes erosive disease whereas anabolic signal- ling (e.g., Wnt and fibroblast growth factor (FGF)18) favours the formation of new bone including bony spurs and subchondral sclerosis. Other pathways may have a dual function in arthritis (e.g., hedgehog) leading to either catabolic or anabolic joint remodelling dependent on other factors. Key mediators within these signalling pathways may serve as novel targets for treating pathological remodelling of bone and cartilage in arthritis. Molecular pathways govern remodelling processes of bone and cartilage in arthritic joints. Future therapies will likely target the pathologic activity of these molecular pathways to specifically block either catabolic or anabolic joint remodelling in arthritis. -
Estonian Statistics on Medicines 2016 1/41
Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole -
Sonochemical Synthesis of Cellulose/Hydroxyapatite
www.nature.com/scientificreports OPEN Sonochemical synthesis of cellulose/hydroxyapatite nanocomposites and their Received: 10 January 2018 Accepted: 20 April 2018 application in protein adsorption Published: xx xx xxxx Lian-Hua Fu1,2,3, Chao Qi2, Yan-Jun Liu1, Wen-Tao Cao1 & Ming-Guo Ma 1 Hydroxyapatite (HA) is the main mineral constituent in the hard tissue of vertebrate, which is recognized as an important biomedical material owing to its excellent bioactivity and biocompatibility. Herein, we report a facile and green sonochemical route for the rapid synthesis of cellulose/ HA nanocomposites in NaOH/urea aqueous solution. The in vitro behavior of the cellulose/HA nanocomposites was studied to evaluate the biological response of the nanocomposites following immersion in simulated body fuid for various periods (maximum of 28 days). The HA crystals formed on the surface of the nanocomposites were carbonate-containing apatite, which is similar to the naturally occurring calcium phosphate materials. The HA nanosheets (assembly of nanorods) were mineralized on the surface of the nanocomposites, and maximum mass of the nanocomposites was reached 1.82 times of initial mass after 28 days of soaking. Moreover, the as-prepared cellulose/HA nanocomposites have good cytocompatibility, and show a relatively high protein adsorption ability using hemoglobin as a model protein. These results indicate that the as-prepared cellulose/HA nanocomposites are promising for applications in various biomedical felds such as tissue engineering and protein/drug delivery. Hydroxyapatite (HA) is the main mineral component in the hard tissue of vertebrate bones and teeth as well as the most stable calcium phosphate phase under physiological conditions1,2.